European Respiratory Society statement on long COVID follow-up

Katerina M. Antoniou; Eirini Vasarmidi; Anne Marie Russell; Claire Andrejak; Bruno Crestani; Marion Delcroix; Anh Tuan Dinh-Xuan; Venerino Poletti; Nicola Sverzellati; Michele Vitacca; Martin Witzenrath; Thomy Tonia; Antonio Spanevello

doi:10.1183/13993003.02174-2021

European Respiratory Society statement on long COVID follow-up

Katerina M. Antoniou^*, Eirini Vasarmidi, Anne Marie Russell, Claire Andrejak, Bruno Crestani, Marion Delcroix, Anh Tuan Dinh-Xuan, Venerino Poletti, Nicola Sverzellati, Michele Vitacca, Martin Witzenrath, Thomy Tonia, Antonio Spanevello

^*Corresponding author for this work

Nursing and Midwifery

Research output: Contribution to journal › Review article › peer-review

4 Downloads (Pure)

Abstract

Patients diagnosed with coronavirus disease 2019 (COVID-19) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection frequently experience symptom burden post-acute infection or post-hospitalisation. We aimed to identify optimal strategies for follow-up care that may positively impact the patient’s quality of life (QoL). A European Respiratory Society (ERS) Task Force convened and prioritised eight clinical questions. A targeted search of the literature defined the timeline of “long COVID” as 1–6 months post-infection and identified clinical evidence in the follow-up of patients. Studies meeting the inclusion criteria report an association of characteristics of acute infection with persistent symptoms, thromboembolic events in the follow-up period, and evaluations of pulmonary physiology and imaging. Importantly, this statement reviews QoL consequences, symptom burden, disability and home care follow-up. Overall, the evidence for follow-up care for patients with long COVID is limited.

Original language	English
Article number	2102174
Number of pages	20
Journal	European Respiratory Journal
Volume	60
Issue number	2
DOIs	https://doi.org/10.1183/13993003.02174-2021
Publication status	Published - 4 Aug 2022

Bibliographical note

Funding Information:
Funding support was provided by the European Respiratory Society (TF-2020-14). A-M. Russell is a NIHR 70@70 Senior Research Fellow. The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health Research or the Dept of Health and Social Care. Funding information for this article has been deposited with the Crossref Funder Registry.

Publisher Copyright:
Copyright © The authors 2022.

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1183/13993003.02174-2021Licence: Creative Commons: Attribution-NonCommercial (CC BY-NC)

AntoniouK2022EuropeanFinal published version, 741 KBLicence: Creative Commons: Attribution-NonCommercial (CC BY-NC)

Cite this

@article{d53d2620f5904de1b9dc7f70eb91bf54,

title = "European Respiratory Society statement on long COVID follow-up",

abstract = "Patients diagnosed with coronavirus disease 2019 (COVID-19) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection frequently experience symptom burden post-acute infection or post-hospitalisation. We aimed to identify optimal strategies for follow-up care that may positively impact the patient{\textquoteright}s quality of life (QoL). A European Respiratory Society (ERS) Task Force convened and prioritised eight clinical questions. A targeted search of the literature defined the timeline of “long COVID” as 1–6 months post-infection and identified clinical evidence in the follow-up of patients. Studies meeting the inclusion criteria report an association of characteristics of acute infection with persistent symptoms, thromboembolic events in the follow-up period, and evaluations of pulmonary physiology and imaging. Importantly, this statement reviews QoL consequences, symptom burden, disability and home care follow-up. Overall, the evidence for follow-up care for patients with long COVID is limited.",

author = "Antoniou, {Katerina M.} and Eirini Vasarmidi and Russell, {Anne Marie} and Claire Andrejak and Bruno Crestani and Marion Delcroix and Dinh-Xuan, {Anh Tuan} and Venerino Poletti and Nicola Sverzellati and Michele Vitacca and Martin Witzenrath and Thomy Tonia and Antonio Spanevello",

note = "Funding Information: Funding support was provided by the European Respiratory Society (TF-2020-14). A-M. Russell is a NIHR 70@70 Senior Research Fellow. The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health Research or the Dept of Health and Social Care. Funding information for this article has been deposited with the Crossref Funder Registry. Publisher Copyright: Copyright {\textcopyright} The authors 2022.",

year = "2022",

month = aug,

day = "4",

doi = "10.1183/13993003.02174-2021",

language = "English",

volume = "60",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "2",

}

TY - JOUR

T1 - European Respiratory Society statement on long COVID follow-up

AU - Antoniou, Katerina M.

AU - Vasarmidi, Eirini

AU - Russell, Anne Marie

AU - Andrejak, Claire

AU - Crestani, Bruno

AU - Delcroix, Marion

AU - Dinh-Xuan, Anh Tuan

AU - Poletti, Venerino

AU - Sverzellati, Nicola

AU - Vitacca, Michele

AU - Witzenrath, Martin

AU - Tonia, Thomy

AU - Spanevello, Antonio

N1 - Funding Information: Funding support was provided by the European Respiratory Society (TF-2020-14). A-M. Russell is a NIHR 70@70 Senior Research Fellow. The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health Research or the Dept of Health and Social Care. Funding information for this article has been deposited with the Crossref Funder Registry. Publisher Copyright: Copyright © The authors 2022.

PY - 2022/8/4

Y1 - 2022/8/4

N2 - Patients diagnosed with coronavirus disease 2019 (COVID-19) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection frequently experience symptom burden post-acute infection or post-hospitalisation. We aimed to identify optimal strategies for follow-up care that may positively impact the patient’s quality of life (QoL). A European Respiratory Society (ERS) Task Force convened and prioritised eight clinical questions. A targeted search of the literature defined the timeline of “long COVID” as 1–6 months post-infection and identified clinical evidence in the follow-up of patients. Studies meeting the inclusion criteria report an association of characteristics of acute infection with persistent symptoms, thromboembolic events in the follow-up period, and evaluations of pulmonary physiology and imaging. Importantly, this statement reviews QoL consequences, symptom burden, disability and home care follow-up. Overall, the evidence for follow-up care for patients with long COVID is limited.

AB - Patients diagnosed with coronavirus disease 2019 (COVID-19) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection frequently experience symptom burden post-acute infection or post-hospitalisation. We aimed to identify optimal strategies for follow-up care that may positively impact the patient’s quality of life (QoL). A European Respiratory Society (ERS) Task Force convened and prioritised eight clinical questions. A targeted search of the literature defined the timeline of “long COVID” as 1–6 months post-infection and identified clinical evidence in the follow-up of patients. Studies meeting the inclusion criteria report an association of characteristics of acute infection with persistent symptoms, thromboembolic events in the follow-up period, and evaluations of pulmonary physiology and imaging. Importantly, this statement reviews QoL consequences, symptom burden, disability and home care follow-up. Overall, the evidence for follow-up care for patients with long COVID is limited.

UR - http://www.scopus.com/inward/record.url?scp=85130163405&partnerID=8YFLogxK

U2 - 10.1183/13993003.02174-2021

DO - 10.1183/13993003.02174-2021

M3 - Review article

C2 - 35144991

AN - SCOPUS:85130163405

SN - 0903-1936

VL - 60

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 2

M1 - 2102174

ER -

European Respiratory Society statement on long COVID follow-up

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this